Gilead Sciences: HIV Infections trials

The registry lists 77 HIV Infections studies with Gilead Sciences as lead sponsor. 2 are open to participants now and 33 have results posted.

Phase 1 13Phase 2 16Phase 3 31Phase 4 12No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRecruitingNCT07682961Phase 3
• Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionRecruitingNCT07473778
• Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsTerminatedNCT05458102Phase 1Results posted
• Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionCompletedNCT04811040Phase 1Results posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionCompletedNCT02480712Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-InfectionCompletedNCT02457611Phase 2Results posted
• Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedNCT01968551Phase 3Results posted
• Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedNCT01967940Phase 3Results posted
• Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric ParticipantsTerminatedNCT01923311Phase 2/3Results posted
• Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenCompletedNCT01854775Phase 2/3Results posted
• Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedNCT01818596Phase 3Results posted
• Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedNCT01815736Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01797445Phase 3Results posted
• A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01783678Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01780506Phase 3Results posted
• Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in AdolescentsCompletedNCT01721109Phase 2/3Results posted
• Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenCompletedNCT01705574Phase 3Results posted
• Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01667731Phase 3Results posted
• D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsCompletedNCT01565850Phase 2Results posted
• Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01533259Phase 3Results posted
• Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01497899Phase 2Results posted
• Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01495702Phase 3Results posted
• Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01475838Phase 3Results posted
• Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected AdultsCompletedNCT01440569Phase 3Results posted
• Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedNCT01363011Phase 3Results posted
• Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01108510Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01106586Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01095796Phase 3Results posted
• Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT00869557Phase 2Results posted
• Safety and Efficacy Study of Switching From Epzicom to TruvadaCompletedNCT00724711Phase 4Results posted
• Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirCompletedNCT00708162Phase 3Results posted
• Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected ChildrenCompletedNCT00528957Phase 3Results posted
• Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral TherapyCompletedNCT00352053Phase 3Results posted
• TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily TruvadaCompletedNCT00323492Phase 4Results posted
• Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected SubjectsCompletedNCT00112047Phase 3Results posted
• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingNCT02016924Phase 2/3
• A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USACompletedNCT01865799
• A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP IndicationCompletedNCT01865786
• A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected SubjectsCompletedNCT01850212
• Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male VolunteersCompletedNCT00648817Phase 4
• Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL TrialCompletedNCT00643968Phase 4
• An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric SubjectsCompletedNCT00642291Phase 2
• ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation TrialCompletedNCT00615810Phase 4
• ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to AtriplaCompletedNCT00615745Phase 4
• Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected PatientsCompletedNCT00365612Phase 4
• GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With ResistanceCompletedNCT00362687Phase 4
• Safety Study of Once a Day ART and Opiate Substitute.CompletedNCT00324688Phase 4
• SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV InfectionCompletedNCT00323544Phase 3
• Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.CompletedNCT00298350Phase 2
• Combination of Efavirenz and Truvada - COMET StudyCompletedNCT00224458Phase 4
• Boosted Atazanavir and Truvada Given Once-Daily - BATON StudyCompletedNCT00224445Phase 4
• Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.CompletedNCT00158821Phase 3
• Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV SubjectsCompletedNCT00121979Phase 2
• Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 PatientsCompletedNCT00106379Phase 4
• A 14-Day Study of Racivir When Used in Combination in HIV-Infected MalesCompletedNCT00040300Phase 1
• A Study of DPC 817 in HIV-Infected MalesCompletedNCT00040274Phase 1
• A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive PatientsCompletedNCT00036634Phase 1/2
• Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00016588Not applicable
• Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug CombinationsStatus unknownNCT00011089Not applicable
• The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected PatientsStatus unknownNCT00007436Phase 3
• A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV InfectionCompletedNCT00002453Not applicable
• Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected PatientsCompletedNCT00002450Phase 3
• A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive PatientsCompletedNCT00002426Not applicable
• Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected PatientsCompletedNCT00002415Phase 2
• Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug CombinationsCompletedNCT00002398Not applicable
• The Safety and Effectiveness of PMPA Prodrug in HIV-Infected PatientsStatus unknownNCT00002396Phase 1
• The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV DrugsCompletedNCT00002379Phase 2
• The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected PatientsCompletedNCT00002346Phase 1
• The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected PatientsCompletedNCT00002327Phase 1
• The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected PatientsCompletedNCT00002326Phase 1
• Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected ChildrenStatus unknownNCT00002219Phase 2
• A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV DrugsCompletedNCT00002206Phase 1
• A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected PatientCompletedNCT00002184Phase 2
• A Study of PMPA in HIV-Infected PatientsCompletedNCT00002180Phase 1
• A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3CompletedNCT00002161Not applicable
• Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected PatientsCompletedNCT00002128Phase 1
• A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.CompletedNCT00002115Phase 1